Cited by 218Fatty Acid Research and HealthAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease

Open access

Astarita, Giuseppe, Jung, Kwang-Mook, Berchtold, Nicole C., Nguyen, Vinh Q., Gillen, Daniel L., Head, Elizabeth, Cotman, Carl W., Piomelli, Daniele·2010·PLoS ONE

DOI 10.1371/journal.pone.0012538PMC PMC2935886

Open this paper in CoChat — free account

Abstract

Reduced brain levels of docosahexaenoic acid (C22:6n-3), a neurotrophic and neuroprotective fatty acid, may contribute to cognitive decline in Alzheimer's disease. Here, we investigated whether the liver enzyme system that provides docosahexaenoic acid to the brain is dysfunctional in this disease. Docosahexaenoic acid levels were reduced in temporal cortex, mid-frontal cortex and cerebellum of subjects with Alzheimer's disease, compared to control subjects (P = 0.007). Mini Mental State Examination (MMSE) scores positively correlated with docosahexaenoic/α-linolenic ratios in temporal cortex (P = 0.005) and mid-frontal cortex (P = 0.018), but not cerebellum. Similarly, liver docosahexaenoic acid content was lower in Alzheimer's disease patients than control subjects (P = 0.011). Liver docosahexaenoic/α-linolenic ratios correlated positively with MMSE scores (r = 0.78; P<0.0001), and negatively with global deterioration scale grades (P = 0.013). Docosahexaenoic acid precursors, including tetracosahexaenoic acid (C24:6n-3), were elevated in liver of Alzheimer's disease patients (P = 0.041), whereas expression of peroxisomal d-bifunctional protein, which catalyzes the conversion of tetracosahexaenoic acid into docosahexaenoic acid, was reduced (P = 0.048). Other genes involved in docosahexaenoic acid metabolism were not affected. The results indicate that a deficit in d-bifunctional protein activity impairs docosahexaenoic acid biosynthesis in liver of Alzheimer's disease patients, lessening the flux of this neuroprotective fatty acid to the brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0012538

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Overview of docosahexaenoic acid biosynthesis in liver. Diet-derived α-linolenic acid (C18:3n-3) is transformed into tetracosahexaenoic acid (C24:6n-3) by the sequential action of Δ6 and Δ5 desaturases (encoded by the FADS2 and FADS1 genes, respectively) and elongases (such as that encoded by the HELO1 gene) present in the endoplasmatic reticulum. Tetracosahexaenoic acid is transported into peroxisomes (shaded area), presumably by proteins encoded by the ABCD1 or ABCD2 genes, and then converted into docosahexaenoic acid (C22:6n-3) by sequential action of acyl coenzyme-A oxidase (encoded by the ACOX1 gene), d-bifunctional protein (encoded by the HSD17B4 gene), and various peroxisomal thiolases (not shown). The figure shows chemical structures of fatty acids quantified in our analyses.CC BY · PubMed Central

Figure 2 Liver metabolism in Alzheimer's disease patients. Levels of free docosahexaenoic acid (Panel A) and 1-O-1′-(Z)-octadecenyl, 2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (Panel B) in liver tissue from control subjects (open squares) and Alzheimer's disease patients (closed circles). Correlation between individual docosahexaenoic/α-linolenic ratios in liver and most recent Mini-Mental State Examination scores (Panel C) or global deterioration scale grades (Panel D). HSD17B4 mRNA, encoding for d-bifunctional protein (Panel E) and pristanic acid levels (Panel F) in liver from control subjects (open squares) and subjects with Alzheimer's disease (closed circles). Lipid content is expressed in nanomoles per gram of wet tissue and mRNA levels are expressed in arbitrary units. There were statistically detectable differences between control subjects and Alzheimer's disease patients in the levels of docosahexaenoic acid (P = 0.0077) and 1-O-1′-(Z)-octadecenyl, 2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (P = 0.003) by two-tailed Welch's t-test. There was a significant correlation between docosahexaenoic/α-linolenic ratios in liver and Mini-Mental State Examination scores with use of the partial correlation analysis after adjustment for age, gender and post mortem interval. Global deterioration scale grades correlate significantly (P = 0.013) with the docosahexaenoic/α-linolenic ratios using a linear regression analysis adjusting for age, gender and post mortem interval. There were statistically detectable differences between control subjects and patients in the levels of HSD17B4 mRNA (P = 0.048) and pristanic acid (P = 0.0009) by two-tailed Welch's t-test.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity
White, H. (1980) · Econometrica · doi:10.2307/1912934 · Cited by 25,861
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Origins and evolution of the Western diet: health implications for the 21st century1,2
Cordain, L., Eaton, S. B., Sebastian, A., Mann, N., Lindeberg, S., Watkins, B. A., O’Keefe, J. H., & Brand-Miller, J. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn.81.2.341 · Cited by 2,397
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Alzheimer’s disease
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Conversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults
Burdge, G. C., & Calder, P. C. (2005) · Reproduction Nutrition Development · doi:10.1051/rnd:2005047 · Cited by 939
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease
Lukiw, W. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25420 · Cited by 897
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress
Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., & Bazan, N. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402531101 · Cited by 753 · cited 1×
“The polyunsaturated lipid, docosahexaenoic acid (C22:6n-3), is an essential component of neuronal membranes [4,5] and a precursor for potent neuroprotective mediators [6–8].”
Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model
Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., Rostaing, P., Triller, A., Salem, N., Ashe, K. H., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.013 · Cited by 707
Dietary omega 3 fatty acids and the developing brain
Innis, S. M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.078 · Cited by 699
A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model
Lim, G. P., Calon, F., Morihara, T., Yang, F., Teter, B., Ubeda, O. J., Salem, N., Frautschy, S. A., & Cole, G. M. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4225-04.2005 · Cited by 697
Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease
Söderberg, M., Edlund, C., Kristensson, K., & Dallner, G. (1991) · Lipids · doi:10.1007/bf02536067 · Cited by 667
The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase.
Voss, A., Reinhart, M., Sankarappa, S. K., & Sprecher, H. W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54882-1 · Cited by 665
Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry
Han, X., Holtzman, D. M., & McKeel, D. W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00332.x · Cited by 571
Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids.
Sprecher, H. W., Luthria, D. L., Mohammed, B. S., & Baykousheva, S. P. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41084-3 · Cited by 517
Membrane docosahexaenoate is supplied to the developing brain and retina by the liver.
Scott, B. L., & Bazan, N. G. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.8.2903 · Cited by 448
Regional Membrane Phospholipid Alterations in Alzheimer's Disease
Prasad, M. R., Lovell, M. A., Yatin, M., Dhillon, H. S., & Markesbery, W. R. (1998) · Neurochemical Research · doi:10.1023/a:1022457605436 · Cited by 440
Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors
Bazan, N. G. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.03.005 · Cited by 353
Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels
Green, K. N., Martínez‐Coria, H., Khashwji, H., Hall, E. B., Yurko‐Mauro, K., Ellis, L., & LaFerla, F. M. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0055-07.2007 · Cited by 336
Fish, docosahexaenoic acid and Alzheimer’s disease
Cunnane, S. C., Plourde, M., Pifferi, F., Bégin, M. E., Féart, C., & Barberger‐Gateau, P. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.04.001 · Cited by 336
Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver
Rapoport, S. I., Rao, J. S., & Igarashi, M. (2007) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2007.10.023 · Cited by 295
DOCOSAHEXAENOIC ACID, FATTY ACID–INTERACTING PROTEINS, AND NEURONAL FUNCTION: Breastmilk and Fish Are Good for You
Marszalek, J. R., & Lodish, H. F. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.122303.120624 · Cited by 270
Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia
Goodenowe, D. B., Cook, L. L., Liu, J., Lu, Y., Jayasinghe, D., Ahiahonu, P. W. K., Heath, D., Yamazaki, Y., Flax, J., Krenitsky, K. F., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p700023-jlr200 · Cited by 259
Docosahexaenoic Acid and the Aging Brain
Lukiw, W. J., & Bazan, N. G. (2008) · Journal of Nutrition · doi:10.3945/jn.108.096016 · Cited by 256
Decrease and Structural Modifications of Phosphatidylethanolamine Plasmalogen in the Brain with Alzheimer Disease
Guan, Z., Wang, Y., Cairns, N. J., Lantos, P. L., Dallner, G., & Sindelar, P. J. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199907000-00008 · Cited by 236
Fatty Acid Composition of Frontal, Temporal and Parietal Neocortex in the Normal Human Brain and in Alzheimer’s Disease
Fraser, T., Tayler, H. M., & Love, S. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0087-5 · Cited by 207
Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders
Martínez, M. (1992) · Brain Research · doi:10.1016/s0006-8993(10)80021-6 · Cited by 190
Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid
Moore, S. A., Hurt, E., Yoder, E. J., Sprecher, H. W., & Spector, A. A. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39724-8 · Cited by 171
Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects
SKINNER, E. R., Watt, C., BESSON, J. A. O., & Best, P. V. (1993) · Brain · doi:10.1093/brain/116.3.717 · Cited by 137
Peroxisomal Straight-chain Acyl-CoA Oxidase and D-bifunctional Protein Are Essential for the Retroconversion Step in Docosahexaenoic Acid Synthesis
Su, H., Moser, A. B., Moser, H. W., & Watkins, P. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106326200 · Cited by 108
Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content.
Corrigan, F., Horrobin, D., Skinner, E., Besson, J. O., & Cooper, M. (1998) · International Journal of Biochemistry and Cell Biology · doi:10.1016/s1357-2725(97)00125-8 · Cited by 102
Severe deficiency of docosahexaenoic acid in peroxisomal disorders
Martínez, M. (1990) · Neurology · doi:10.1212/wnl.40.8.1292 · Cited by 102
Nutrition and the Brain
Morley, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.11.005 · Cited by 87
Physiological Role of D-3-Hydroxyacyl-CoA Dehydratase/D-3-Hydroxyacyl-CoA Dehydrogenase Bifunctional Protein
Jiang, L., Kurosawa, T., Sato, M., Suzuki, Y., & Hashimoto, T. (1997) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021615 · Cited by 86
Decreased content of docosahexaenoate and arachidonate in plasma phospholipids in usher's syndrome
Bazan, N. G., Scott, B. L., Reddy, T. S., & Pelias, M. Z. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(86)80215-7 · Cited by 78
Quantitative contributions of diet and liver synthesis to docosahexaenoic acid homeostasis
Rapoport, S. I., Igarashi, M., & Gao, F. (2010) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.02.015 · Cited by 74
Can the rat liver maintain normal brain DHA metabolism in the absence of dietary DHA?
Rapoport, S. I., & Igarashi, M. (2009) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.05.021 · Cited by 63
Fat Intake and CNS Functioning: Ageing and Disease
Crawford, M. A., Bazinet, R. P., & Sinclair, A. J. (2009) · Annals of Nutrition and Metabolism · doi:10.1159/000229003 · Cited by 62
Lipid abnormalities in the brain in adult Down’s syndrome and Alzheimer’s disease
Brooksbank, B. W. L., & Martínez, M. (1989) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160049 · Cited by 55
Biology of Senescent Liver Peroxisomes: Role in Hepatocellular Aging and Disease
Youssef, J., & Badr, M. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107791 · Cited by 42
Catalase turnover in rat liver and kidney as a function of age
Haining, J. L., & Legan, J. S. (1973) · Experimental Gerontology · doi:10.1016/0531-5565(73)90018-1 · Cited by 41
Liver disease as a risk factor for cognitive decline and dementia: An Under-recognized issue #
Yilmaz, Y. N., & Ozdogan, O. C. (2008) · Hepatology · doi:10.1002/hep.22752 · Cited by 32

Sorted by citations

Functions of plasmalogen lipids in health and disease
Braverman, N. E., & Moser, A. B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.05.008 · Cited by 1,082
Long-chain omega-3 fatty acids and the brain: A review of the independent and shared effects of EPA, DPA and DHA
Dyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
DHA Effects in Brain Development and Function
Lauritzen, L., Brambilla, P., Mazzocchi, A., Harsløf, L. B. S., Ciappolino, V., & Agostoni, C. V. (2016) · Nutrients · doi:10.3390/nu8010006 · Cited by 566
Significance of long chain polyunsaturated fatty acids in human health
Zárate, R., el Jaber-Vazdekis, N., Tejera, N., Pérez, J. A., & Rodríguez, C. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0153-6 · Cited by 573
Homocysteine, B Vitamins, and Cognitive Impairment
Smith, A. D., & Refsum, H. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071715-050947 · Cited by 526

See all 218

Authors: Astarita, G., Jung, K.-M., Berchtold, N. C., Nguyen, V. Q., Gillen, D. L., Head, E., Cotman, C. W., & Piomelli, D.
Affiliations: University of Rome Tor Vergata (IT)
University of California, Irvine (US)
University of Kentucky (US)
Corresponding author: Piomelli, Daniele
ORCID: Astarita, Giuseppe
Jung, Kwang-Mook
Nguyen, Vinh Q.
Gillen, Daniel L.
Head, Elizabeth
Cotman, Carl W.
Piomelli, Daniele
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2010-09-08
Volume: 5
Issue: 9
Pages: e12538
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0012538
PMC: PMC2935886
OpenAlex: W1993630867
Cited by: 218
References: 42
Citations by year: 2026: 3 · 2025: 6 · 2024: 17 · 2023: 9 · 2022: 15 · 2021: 19 · 2020: 16 · 2019: 15 · 2018: 9 · 2017: 18 · 2016: 19 · 2015: 21 · 2014: 14 · 2013: 14 · 2012: 11
FWCI: 11.23
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
UKnowledge (University of Kentucky) (submittedVersion, cc-by)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Figshare (submittedVersion, cc-by)
Funders: Michael J. Fox Foundation for Parkinson's Research (05-901, 211002, P30 AG19610)
Agilent Foundation
Arizona Department of Health Services (P30 AG19610, P50 AG016573, 05-901, 211002, Contract 211002)
Arizona Biomedical Research Commission (P30 AG19610, 05–901, 211002)
University of California, Irvine (P50AG016573)
National Institute on Aging (211002, P01AG000538, P30-AG-19610, AG-016573, P01 AG00538, AG-19610, AG 00538, P50AG016573, P30AG019610, 05-901)
National Institute on Drug Abuse (R01DA012447)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: docosahexaenoic acid, Alzheimer's disease, cognitive impairment, omega-3 fatty acids, temporal cortex, cerebellum
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Docosahexaenoic Acids, Female, Humans, Liver, Male, Neuropsychological Tests, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks